Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Vanderbilt-Ingram Cancer Center, Nashville, TN, United States



Survival: 15.9 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
   
Drugs:
Country: United States
   
City/State/Province: Nashville, TN
   
Hospital: Vanderbilt-Ingram Cancer Center
   
Journal: Link
   
Date: 2/2012

Description:
Patients:
This phase 2 study involved 132 previously treated advanced metastatic melanoma patients who have a BRAF V600-mutation in the cancer cells. The median patient age was 51.5 years and 61% were male.

Treatment:
Patients were treated with the biologic therapy agent vemurafenib, which is a kinase inhibitor specific to a mutation in the protein called BRAF V600E.

Toxicities:
There was one reported treatment-related death due to kidney failure. Joint pain, rash, fatigue, and alopecia were also reported.

Results:
The median overall survival was 15.9 months.

Support:
This study was supported by the pharmaceutical company Hoffmann-LaRoche.

Correspondence: Dr. Jeffrey A. Sosman; email: jeff.sosman@vanderbilt.edu

E-mail to a Friend Email Physician More Information